BIO vs MANE
Bio-Rad Laboratories vs Veradermics, Incorporated — AI-powered side-by-side comparison
BIO
Bio-Rad Laboratories
59
Buy
VS
MANE
Veradermics, Incorporated
69
Buy
| Metric | BIO | MANE |
|---|
| AI Score |
59
|
69
|
| Price |
$379.85
|
$102.81
|
| P/E Ratio |
45.62×
|
-48.05×
|
| ROE |
10.2%
|
57.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
51.9%
|
0.0%
|
| Debt / Equity |
0.17×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
82.3
|
35.5
|
| Beta |
1.047
|
1.3492
|
| Expected Upside |
+0.6%
|
+13.1%
|
AI Committee View
Current Innellis committee reasoning for BIO versus MANE.
MANE leads by 10 points.
MANE scores 69/100 (Buy) versus BIO at 59/100 (Buy).
BIO Committee View
67% agreement
6 analysts
Positive signals support the current rating — news sentiment is positive (+0.57 across 7 articles, 14d). The committee sees sufficient evidence to maintain the constructive view.
Bull Case
- Price-to-book of 1.1x is a discount to asset value — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 43.5 is expensive by classic value standards — Value
- ROE of only 3.1% -- cheap may mean cheap for a reason — Value
- EPS declining -29.6% YoY despite any revenue growth — Growth
MANE Committee View
100% agreement
5 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is sector concentration is already high (hhi 3069.37). The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
Bear Case
- MACD histogram negative -- bearish momentum — Technical